Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 205430, held by Apotex. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 205430 (Guanfacine Hydrochloride), held by Apotex, was first approved by FDA on Jul 25, 2018, with 3 approved supplements and 0 published complete response letters.
Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2018 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 3MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 4MG BASE · tablet, extended release;oral | Guanfacine Hydrochloride | Rx |
| Feb 20, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 29, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 30, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 25, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters